Efficacy and safety of lenvatinib in 124 Japanese patients with anaplastic thyroid cancer

被引：2
|
作者：
Takahashi, Shunji [1 ]
Tahara, Makoto [2 ]
Ito, Koichi [3 ]
Tori, Masayuki [4 ]
Sakata, Yukinori [5 ]
Ishii, Mika [6 ]
Yoishida, Akira [6 ]
机构：
[1] Japanese Fdn Canc Res, Inst Canc, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Tokyo, Japan
[3] Ito Hosp, Tokyo, Japan
[4] Osaka Police Hosp, Osaka, Japan
[5] Eisai Col Ltd, Tokyo, Japan
[6] Kanagawa Hlth Serv Assoc, Yokohama, Kanagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz338.094
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO3 - 3 -
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Case of Pneumothorax after Treatment with Lenvatinib for Anaplastic Thyroid Cancer with Lung Metastasis
    Yamazaki, Haruhiko
    Iwasaki, Hiroyuki
    Yamashita, Toshinari
    Yoshida, Tatsuya
    Suganuma, Nobuyasu
    Yamanaka, Takashi
    Masudo, Katsuhiko
    Nakayama, Hirotaka
    Kohagura, Kaori
    Rino, Yasushi
    Masuda, Munetaka
    CASE REPORTS IN ENDOCRINOLOGY, 2018, 2018
  • [32] Common carotid artery rupture during treatment with lenvatinib for anaplastic thyroid cancer
    Kazufumi Obata
    Iwao Sugitani
    Aya Ebina
    Yoshiya Sugiura
    Kazuhisa Toda
    Shunji Takahashi
    Kazuyoshi Kawabata
    International Cancer Conference Journal, 2016, 5 (4) : 197 - 201
  • [33] Common carotid artery rupture during treatment with lenvatinib for anaplastic thyroid cancer
    Obata, Kazufumi
    Sugitani, Iwao
    Ebina, Aya
    Sugiura, Yoshiya
    Toda, Kazuhisa
    Takahashi, Shunji
    Kawabata, Kazuyoshi
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2016, 5 (04): : 197 - 201
  • [34] Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer
    Iwasaki, Hiroyuki
    Toda, Soji
    Suganuma, Nobuyasu
    Murayama, Daisuke
    Nakayama, Hirotaka
    Masudo, Katsuhiko
    MOLECULAR AND CLINICAL ONCOLOGY, 2020, 12 (02) : 138 - 143
  • [35] Effects of the Japanese Kampo Medicines Rikkunshito, Shakuyakukanzoto and Goreisan on Lenvatinib Plasma Concentrations in Japanese Patients with Thyroid Cancer
    Fujita, Kazuma
    Suzuki, Akifumi
    Nagahama, Mitsuji
    Sugino, Kiminori
    Masaki, Chie
    Ito, Koichi
    Miura, Masatomo
    DRUGS-REAL WORLD OUTCOMES, 2025, 12 (01) : 153 - 160
  • [36] Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results.
    Takahashi, Shunji
    Kiyota, Naomi
    Yamazaki, Tomoko
    Chayahara, Naoko
    Nakano, Kenji
    Inagaki, Lina
    Toda, Kazuhisa
    Enokida, Tomohiro
    Minami, Hironobu
    Imamura, Yoshinori
    Sasaki, Tatsuya
    Suzuki, Takuya
    Fujino, Katsuki
    Dutcus, Corina
    Tahara, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer
    Haruhiko Yamazaki
    Tomoyuki Yokose
    Hiroyuki Hayashi
    Hiroyuki Iwasaki
    Sachie Osanai
    Nobuyasu Suganuma
    Hirotaka Nakayama
    Katsuhiko Masudo
    Yasushi Rino
    Munetaka Masuda
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 649 - 654
  • [38] Lenvatinib Administration for Anaplastic Thyroid Carcinoma with Brain Metastasis
    Obayashi, Atsuto
    Aoki, Kazuma
    Wada, Tadayoshi
    Furuie, Hiromi
    Kuraoka, Kazuya
    Hamamoto, Takao
    Tatsukawa, Takaharu
    ACTA MEDICA OKAYAMA, 2023, 77 (02) : 227 - 232
  • [39] Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer
    Yamazaki, Haruhiko
    Yokose, Tomoyuki
    Hayashi, Hiroyuki
    Iwasaki, Hiroyuki
    Osanai, Sachie
    Suganuma, Nobuyasu
    Nakayama, Hirotaka
    Masudo, Katsuhiko
    Rino, Yasushi
    Masuda, Munetaka
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (04) : 649 - 654
  • [40] Lenvatinib in thyroid cancer
    Kang, Seema
    LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (04): : 239 - 239
12345